Latest Content

Surviving Scans While Surviving Breast Cancer

March 26th 2025, 5:00pm

By Felicia Mitchell

Article

Survivors facing new medical concerns may fear the unknown, but perseverance is possible as they navigate unexpected challenges in their new normal.

Progress Reported in Phase 1 Trial of CLD-101 for Recurrent Glioma

March 26th 2025, 4:00pm

By Spencer Feldman

Article

A progress report for a phase 1 trial of CLD-101 in recurrent glioma shows safety and feasibility at multiple intracerebral doses.

FDA Approves Cabometyx for Some Neuroendocrine Tumors

March 26th 2025, 1:44pm

By Alex Biese

Article

The FDA has approved Cabometyx for some patients 12 years old and older with pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors.

Navigating a Colorectal Cancer Diagnosis at a Young Age

March 26th 2025, 1:00pm

By Ryan Scott

Article

Melissa Ursini discussed her experience with a colorectal cancer diagnosis at age 37, highlighting her insights during Colorectal Cancer Awareness Month.

EU Approves Rytelo for Transfusion-Dependent Anemia in Low-Risk MDS

March 25th 2025, 9:00pm

By Ryan Scott

Article

The European Commission has approved Rytelo treatment in transfusion-dependent anemia due to very low–, low– or intermediate-risk myelodysplastic syndrome.

Top 3 Takeaways From ASCO GU 2025

March 25th 2025, 8:16pm

By Dr. Emre Yekedüz

Video

Dr. Emre Yekedüz discusses his top 3 key takeaways from attending the 2025 ASCO Genitourinary (GU) Cancers Symposium.

New Cancer Vaccine, EVM14, Cleared for Investigational Drug Application

March 25th 2025, 7:05pm

By Spencer Feldman

Article

EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach this stage.

Navigating a Diagnosis of Diabetes and Chronic Lymphocytic Leukemia

March 25th 2025, 5:00pm

By Chester Freeman

Article

Managing diabetes and chronic lymphocytic leukemia is challenging, but with proactive care, mindfulness and diet changes, I'm working to balance both.

Olvi-Vec Shows Responses and Tolerable Safety in Small Cell Lung Cancer

March 25th 2025, 4:14pm

By Alex Biese

Article

Positive preliminary data from the phase 1b/2 trial evaluating Olvi-Vec in small cell lung cancer have been announced.

First Patient Dosed with Efti in Phase 3 Trial for Non-Small Cell Lung Cancer

March 25th 2025, 3:34pm

By Spencer Feldman

Article

The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced non-small cell lung cancer.

Raising Awareness for Colorectal Cancer, On the Rise in Younger Adults

March 25th 2025, 1:00pm

By Alex Biese

Article

During Colorectal Cancer Awareness Month, Dr. Shyam Thakkar discussed rates of this disease in young adults, the role of AI and disparities in care.

Global Submission Seeks Approval for Sugemalimab Treatment in NSCLC

March 24th 2025, 9:00pm

By Ryan Scott

Article

An application was submitted to the European Medicines Agency seeking approval for treatment with sugemalimab in stage 3 NSCLC following chemoradiotherapy.

Navigating RRMM: Helpful Resources and Advice for Patients Facing Disease Progression

March 24th 2025, 8:59pm

By Saad Usmani, MD

Video

Panelists discuss how multiple myeloma support resources range from formal organizations like the International Myeloma Foundation and Multiple Myeloma Research Foundation to online patient communities, hospital-based support groups, and specialized social media networks, with advice for newly relapsed patients emphasizing the importance of allowing emotional processing before taking action, seeking second opinions from myeloma specialists, asking detailed questions about all available options including clinical trials, connecting with patients who’ve undergone similar treatments, maintaining hope amid setbacks, and recognizing that relapses, while challenging, often open doors to novel therapeutic approaches that can effectively control the disease for extended periods.

Guidance for Caregivers: Supporting a Loved One Through Late-Line RRMM

March 24th 2025, 8:56pm

By Saad Usmani, MD

Video

Panelists discuss how caregivers supporting loved ones with late-line relapsed/refractory multiple myeloma (RRMM) should prioritize both patient and self-care by establishing sustainable support systems, maintaining open communication with the health care team, educating themselves about treatment options while acknowledging emotional boundaries, creating practical organizational systems for medication management and appointment tracking, seeking respite care when needed, connecting with caregiver support groups for shared experiences, participating in decision-making without overshadowing the patient’s voice, preparing contingency plans for complications, and finding moments of normalcy and joy amid the challenges of advanced disease management.

Effective Communication Strategies: Sharing Concerns With Your Medical Team in Late-Line RRMM

March 24th 2025, 8:54pm

By Saad Usmani, MD

Video

Panelists discuss how effective communication with medical teams in advanced multiple myeloma requires proactive strategies including preparing prioritized question lists before appointments, bringing a designated note-taking advocate to consultations, utilizing patient portals for nonurgent concerns, clearly articulating quality of life impacts rather than just symptom presence, requesting dedicated time for treatment planning discussions, recording conversations (with permission) for later review, maintaining symptom diaries with specific details, and establishing relationships with nurse navigators who can facilitate more timely responses—approaches that collectively ensure patient needs are comprehensively addressed despite the complex nature of late-line treatment decisions.